Plain-English translation of NCT07491900 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called , which is an engineered antibody designed to target and reduce harmful B cells that drive lupus. The medication works by attacking these cells in a new way to potentially control lupus disease activity. Researchers want to find the right dose and learn whether this treatment is safe and helpful for people with moderate to severe lupus.
Current lupus treatments don't work well enough for everyone, and some people can't tolerate them or develop resistance. This medication uses a new approach to eliminate the B cells that cause lupus, potentially offering a better treatment option for people whose disease is not adequately controlled.
You likely qualify if…
You likely don't qualify if…
You would receive the medication as two intravenous infusions given one week apart (on Day 1 and Day 8). Over the next 13 months, you would attend regular study visits to have blood tests, urine tests, and kidney function checks, and complete questionnaires about your lupus symptoms, fatigue, and quality of life. Researchers will carefully monitor you for any side effects and measure how well the medication is working to control your disease.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Australia